TLP
EDIT icon

Tri Locum Partners’s Editas Medicine EDIT Stock Holding History

Tri Locum Partners’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-19,295
Closed -$151K – 31
2023
Q3 		$151K Sell
19,295
-351,582
-95% -$3.01M 0.05% 54
2023
Q2 		$3.05M Buy
+370,877
New +$3.23M 1.13% 26

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Tri Locum Partners's EDIT Position: Q4 2023 in Review

Tri Locum Partners sold out of Editas Medicine (EDIT) in Q4 2023, closing a stake of 19,295 shares — an estimated $151K sold.

Tri Locum Partners first reported a position in EDIT in Q2 2023 and held it in 2 quarters. The position peaked at $3.05M in Q2 2023. 225 funds tracked by Wall St. Rank hold EDIT as of Q4 2023.

  • Tri Locum Partners reported no remaining Editas Medicine position as of Q4 2023 after selling out during the quarter.
  • Tri Locum Partners sold 19,295 Editas Medicine shares in Q4 2023, an estimated $151K.
  • Tri Locum Partners first reported a position in Editas Medicine in Q2 2023 and held it in 2 quarters.
  • Tri Locum Partners's Editas Medicine position peaked at $3.05M in Q2 2023.
  • 225 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2023.

Based on Tri Locum Partners's 13F filing for Q4 2023, filed 14 Feb 2024.